NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

1.00 doesn’t take multiple factors into account. Presumably, the first is “intensively” pursued non-dilutive funding. 1.00 is just a starting/talking point before the rubber hits the road with marketing approval.

1.00 is just a nominal number to throw down in the first but necessary analyst report pre-approval.

As Linda stated, everything else is waiting on MHRA marketing approval.

1.00 will be in the rearview mirror much sooner than later. IMO.

Another ROI, for instance, that people forget, is orphan indication stacking.